Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 901 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Once Weekly Clear all

Conditions: Low Testosterone
Interventions: TAK-448, TAK-448 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 60 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: New Haven, Connecticut • Boynton Beach, Florida • Jacksonville, Florida + 18 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab; Drug · Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Renal Insufficiency
Interventions: Zoledronic Acid, Calcium with vitamin D, Alendronate; Drug · Combination Product
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetes Mellitus, Type 2
Interventions: CagriSema, Placebo CagriSema; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 21
States / cities: Little Rock, Arkansas • San Diego, California • Spring Valley, California + 16 more

Conditions: IgA Nephropathy
Interventions: Placebo, Atacicept 25 mg, Atacicept 75 mg; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2428757, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Bermuda Dunes, California • Chula Vista, California • Huntington Beach, California + 12 more

Conditions: Atherosclerosis
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Thyroid Gland Anaplastic Carcinoma
Interventions: Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride, Placebo Administration; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 130
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 100 more

Conditions: Cocaine Dependence
Interventions: Clavulanic Acid Only Product, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Charleston, South Carolina

Conditions: Cancer
Interventions: Acupuncture and questionnaires, placebo acupuncture; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Basking Ridge, New Jersey • New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Osimertinib, Lazertinib, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,074 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 20
States / cities: Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more

Conditions: Systemic Lupus Erythematosus
Interventions: A-623, Placebo Comparator; Drug · Other
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 11 more

Conditions: Arthritis, Psoriatic
Interventions: Tofacitinib, Methotrexate, Placebo Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more

Conditions: Healthy, Non-Smoking
Interventions: varenicline, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Rheumatoid Arthritis
Interventions: Abatacept or Placebo (both as IV & SC solution), Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 5
States / cities: Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more

Conditions: Diabetes Mellitus
Interventions: SYR-472, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 51
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 48 more

Conditions: Cocaine Dependence
Interventions: Galantamine, Computer Assisted Cognitive Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Bridgeport, Connecticut • Stratford, Connecticut

Conditions: Disorders of Gut-brain Interaction
Interventions: Active Therapeutic acupuncture intervention, Sham therapeutic acupuncture treatment; Other
Lead sponsor: Children's Hospital of Orange County; Other
Eligibility: 8 Years to 17 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Irvine, California

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more

Conditions: Hypercholesterolemia, Heterozygous Familial
Interventions: mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 20
States / cities: Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more

Conditions: Diabetes Mellitus, Type 2
Interventions: CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miramar, Florida • San Antonio, Texas • Tacoma, Washington

Conditions: Obesity
Interventions: Ribupatide, Semaglutide, Placebo; Drug
Lead sponsor: Kailera; Industry
Eligibility: 18 Years and older
Enrollment: 1,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more

Conditions: Graft Versus Host Disease
Interventions: Prochymal®, Placebo, Corticosteroid; Drug · Other
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 45
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more

Search by objective public record fields.

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

Efficacy and Safety of Atacicept in IgA Nephropathy

A Study for Patients With Type 2 Diabetes Mellitus

The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

Acupuncture Therapy for Pediatric Disorders of Gut-Brain Interaction

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)